| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | SB1DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 6 | NIH | 5/20/2025 | $0 |
| | 2025 | 2022 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 6 | NIH | 5/22/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $290,351 ) |
| | 2024 | 2024 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | R41AI179525 | Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis | 000 | 2 | NIH | 8/7/2024 | $290,351 |
|
| Issue Date FY: 2023 ( Subtotal = $505,363 ) |
| | 2023 | 2023 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | R41AI179525 | Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis | 000 | 1 | NIH | 8/31/2023 | $304,921 |
| | 2023 | 2023 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | SB1DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 001 | 6 | NIH | 7/31/2023 | $200,442 |
| | 2023 | 2022 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | SB1DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 5 | NIH | 5/31/2023 | $0 |
| | 2023 | 2022 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 6 | NIH | 1/17/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,070,736 ) |
| | 2022 | 2022 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | SB1DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 5 | NIH | 8/1/2022 | $1,094,718 |
| | 2022 | 2022 | GLYCOMIRA LLC | 160 GREENTREE DR | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 6 | NIH | 5/17/2022 | $976,018 |
|
| Issue Date FY: 2021 ( Subtotal = $2,530,846 ) |
| | 2021 | 2021 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 001 | 5 | NIH | 6/24/2021 | $999,953 |
| | 2021 | 2021 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | SB1DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 4 | NIH | 9/20/2021 | $1,530,893 |
| | 2021 | 2020 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 4 | NIH | 6/24/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $783,698 ) |
| | 2020 | 2020 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 4 | NIH | 1/30/2020 | $783,698 |
| | 2020 | 2017 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 3 | NIH | 4/11/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $841,614 ) |
| | 2019 | 2019 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 3 | NIH | 1/28/2019 | $841,614 |
| | 2019 | 2016 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R43AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 1 | NIH | 4/25/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $775,153 ) |
| | 2018 | 2018 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 2 | NIH | 2/5/2018 | $781,547 |
| | 2018 | 2016 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R43AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 1 | NIH | 2/5/2018 | $0 |
| | 2018 | 2015 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 000 | 3 | NIH | 1/30/2018 | -$6,394 |
|
| Issue Date FY: 2017 ( Subtotal = $381,446 ) |
| | 2017 | 2017 | GLYCOMIRA, LLC | 160 GREENTREE DR STE 101 | DOVER | DE | 19904-7620 | KENT | USA | R44DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 3 | NIH | 8/18/2017 | $381,446 |
|
| Issue Date FY: 2016 ( Subtotal = $662,480 ) |
| | 2016 | 2016 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43AI126987 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis | 000 | 1 | NIH | 7/28/2016 | $297,614 |
| | 2016 | 2016 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 2 | NIH | 8/16/2016 | $364,866 |
| | 2016 | 2014 | GLYCOMIRA LLC | 675 ARAPEEN DRIVE | SALT LAKE CITY | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 000 | 3 | NIH | 5/31/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $7,000 ) |
| | 2015 | 2015 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 000 | 3 | NIH | 4/27/2015 | $2,000 |
| | 2015 | 2015 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 001 | 3 | NIH | 6/9/2015 | $5,000 |
|
| Issue Date FY: 2014 ( Subtotal = $885,154 ) |
| | 2014 | 2014 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 000 | 3 | NIH | 6/23/2014 | $685,157 |
| | 2014 | 2014 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43DE024024 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis | 000 | 1 | NIH | 6/14/2014 | $199,997 |
|
| Issue Date FY: 2013 ( Subtotal = $814,843 ) |
| | 2013 | 2013 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 000 | 2 | NIH | 9/19/2013 | $717,386 |
| | 2013 | 2013 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 002 | 2 | NIH | 9/24/2013 | $115,742 |
| | 2013 | 2013 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R44DE022216 | Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis | 001 | 2 | NIH | 9/20/2013 | -$18,285 |
|
| Issue Date FY: 2011 ( Subtotal = $620,024 ) |
| | 2011 | 2011 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43DK093413 | NOVEL GLYCOSAMINOGLYCAN DERIVATIVES FOR TREATMENT OF BLADDER INFLAMMATION | 000 | 1 | NIH | 9/15/2011 | $200,024 |
| | 2011 | 2011 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43CA153452 | NOVEL GLYCOSAMINOGLYCAN ETHERS FOR PREVENTION OF METASTASIS | 000 | 1 | NIH | 9/23/2011 | $210,000 |
| | 2011 | 2011 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43DE022216 | ANTI-INFLAMMATORY GLYCOSAMINOGLYCAN ETHERS FOR TREATMENT OF PERIODONTITIS | 000 | 1 | NIH | 7/29/2011 | $210,000 |
|
| Issue Date FY: 2009 ( Subtotal = $289,800 ) (Continued on the next page) |
| | 2009 | 2009 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43EY019786 | SULFATED POLYSACCHARIDE DERIVATIVES FOR TREATMENT OF MACULAR DEGENERATION | 000 | 1 | NIH | 9/11/2009 | $140,000 |
| | 2009 | 2009 | GLYCOMIRA, LLC | 201 E South Temple # 618 | Salt Lake City | UT | 84108 | SALT LAKE | USA | R43AR057281 | SULFATED POLYSACCHARIDE DERIVATIVES FOR THE TREATMENT OF ROSACEA | 000 | 1 | NIH | 4/23/2009 | $149,800 |
|
